Table 3.
hepatitis B, C and D outcomes for selected subsets from the CODE adult cohort (2004)
| Adult cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Age groups (years) | 18 to <25 | 25 to <30 | ≥30 | ||||||
| Overall N=75 | HIV+ N=21 | HIV- N=54 | Overall N=35 | HIV+ N=20 | HIV- N=15 | Overall N=64 | HIV+ N=38 | HIV- N=26 | |
| Male gender | 30/75 (40.0%) | 5/21 (23.8%) | 25/54 (46.3%) | 11/35 (31.4%) | 4/20 (20.0%) | 7(15 (46.7%) | 27/64 (42.2%) | 17/38 (44.7%) | 10/26 (38.5%) |
| HBsAg+ | 21/75 | 2/21 | 19/54 | 7/35 | 3/20 | 4/15 | 14/64 | 4/38 | 10/26 |
| HBeAg+ | 6/21 (28.6%) | 1/2 (50.0%) | 5/19 (26.3%) | 2/7 (28.6%) | 1/3 (33.3%) | 1/4 (25.0%) | 2/14 (14.3%) | 0/4 (0.0%) | 2/10 (20.0%) |
| Anti-HBe+ | 15/21 (71.4%) | 1/2 (50.0%) | 14/19 (73.7%) | 6/7 (85.7%) | 2/3 (66.7%) | 4/4 (100.0%) | 10/14 (71.4%) | 4/4 (100.0%) | 6/10 (60.0%) |
| Anti-HBs+ only | 2/75 (2.7%) | 1/21 (4.8%) | 1/54 (1.9%) | 0/35 (0.0%) | 0/20 (0.0%) | 0/15 (0.0%) | 1/64 (1.6%) | 0/38 (0.0%) | 1/26 (3.9%) |
| Anti-HBc+ total | 30/75 (40.0%)) | 17/21 (81.0%) | 13/54 (24.1%) | 20/35 (57.1%) | 15/20 (75.0%) | 5/15 (33.3%) | 42/64 (65.6%) | 32/38 (84.2%) | 10/26 (38.5%) |
| HBV naive | 20/75 (26.7%) | 1/21 (4.8%) | 19/54 (35.2%) | 8/35 (22.9%) | 2/20 (10.0%) | 6/15 (40.0%) | 6/64 (9.4%) | 2/38 (5.3%) | 4/26 (15.4%) |
| HCV+ | 1/75 (1.3%) | 0 | 1/64 (1.6%) | ||||||
| HDV+ | 0 | 0 | 1/64 (1.6%) | ||||||
Data is indicated in numbers (%); HBsAg=hepatitis B surface antigen; HBeAg=hepatitis B e antigen; anti-HBe= hepatitis B e antibodies; HBV=hepatitis B; HCV=hepatitis C; HDV=hepatitis delta antigen, note: the proportions between HIV+ and HIV- do not correspond to HIV prevalence, as samples were selected purposively by HIV status, the proportions between HBsAg+ and HBsAg- do not correspond to prevalence of HBsAg, as adult samples were selected purposively by HBsAg status; * are indicating the denominators that are smaller than in the overall group